雅虎香港 搜尋

搜尋結果

  1. 2016年6月23日 · Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe.

  2. www.sanofi.com › en › your-healthVaccines - Sanofi

    2023 Profile of Sanofi's Vaccines Business Unit References World Health Organization (2019) Immunization Facts in Pictures. Accessed October 2022 MAT-GLB-2200131 v2 – 12/2022 Page updated December 2022 Continue to Your Health Follow us Back to ...

  3. 2023年7月24日 · Base de données publique des médicaments ANSM - Mis à jour le : 24/07/2023 Dénomination du médicament VAXIGRIPTETRA, suspension injectable en seringue préremplie Vaccin grippal quadrivalent (inactivé, à virion fragmenté)

  4. Attachment 1: Product AusPAR - Vaxigrip Tetra - Inactivated quadrivalent influenza vaccine (split virion) - Sanofi-Aventis Australia Pty Ltd - PM-2018-00583-1-2 FINAL 19 December 2019. This Product information was approved at the time this AusPAR was published.

  5. 2023年2月27日 · 近日,赛诺菲中国宣布,四价流感病毒裂解疫苗—凡尔佳® (VaxigripTetra®)6~35月龄适应症于2023年2月21日获得国家药品监督管理局 (NMPA)上市许可批准 ...

  6. Vaccines, Inactivated. vaxigrip. VaxigripTetra™ (IIV4; Sanofi Pasteur) is a quadrivalent split-virion influenza vaccine approved in Europe in 2016 for individuals ≥ 3 years of age. IIV4 builds on the well-established record of the trivalent split-virion influenza vaccine (Vaxigrip®). Areas covered: This literature review summarizes ….

  7. Microsoft Word - 1.4.3 VaxigripTetra PI NH20-21_proposed_Aug2020. 1. NAME OF THE MEDICINAL PRODUCT. VaxigripTetra, suspension for injection in pre-filled syringe. Quadrivalentinfluenza vaccine (split virion, inactivated) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Influenza virus (inactivated, split) of the following strains*: